TRAVERE THERAPEUTICS, INC. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
TRAVERE THERAPEUTICS, INC. (TVTX) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 11.39 million shares for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-10-30.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2025-10-30
- TRAVERE THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2025-09-30 was 11.39M shares.
- TRAVERE THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2016-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2016-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2015-09-30 was 2.64M shares.
- TRAVERE THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2017 was 0.00 shares.
- TRAVERE THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2016 was 0.00 shares, a 100.00% decline from fiscal 2015.
- TRAVERE THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2015 was 2.64M shares.
- TRAVERE THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2014 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month |
|---|---|---|---|---|
| 2025-09-30 | 11.39M shares 10-Q · filed 2025-10-30 | |||
| 2017-12-31 | 0.00 shares 10-K · filed 2018-07-06 | |||
| 2016-12-31 | 0.00 shares 10-K · filed 2018-07-06 | |||
| 2016-09-30 | 0.00 shares 10-Q · filed 2016-11-04 | 0.00 shares 10-Q · filed 2016-11-04 | ||
| 2016-06-30 | 0.00 shares 10-Q · filed 2016-08-05 | |||
| 2016-03-31 | 0.00 shares 10-Q · filed 2016-05-05 | |||
| 2015-12-31 | 2.64M shares 10-K · filed 2018-07-06 | |||
| 2015-09-30 | 2.64M shares 10-Q · filed 2016-11-04 | 2.64M shares 10-Q · filed 2016-11-04 | ||
| 2015-06-30 | 2.64M shares 10-Q · filed 2016-08-05 | |||
| 2015-03-31 | 2.64M shares 10-Q · filed 2016-05-05 | |||
| 2014-12-31 | 0.00 shares 10-K · filed 2017-03-01 | |||
| 2014-09-30 | 0.00 shares 10-Q · filed 2015-11-06 | 0.00 shares 10-Q · filed 2015-11-06 | ||
| 2013-12-31 | 0.00 shares 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |